Death is an easy metric to track. It’s binary and final, which makes it the simplest thing in the world for a researcher to count, but it’s a remarkably noisy signal for longevity.

We’ve built an entire industry around pushing the "end date" further into the future while systematically ignoring the Diagnostic Cliff. There’s a massive difference between a 90-year-old who’s spent twenty years on a cocktail of statins and antihypertensives and one who walks into the clinic for the first time at 89. That isn't just a matter of "quality of life." It’s a fundamental difference in systemic stoichiometric flux.

In my work on hepatic NAD+ kinetics, I see this constantly. The liver acts as a metabolic shock absorber, masking peripheral decline until the system hits a tipping point. By the time a chronic disease actually appears on a chart, the bioenergetic war has been over for a decade. We're essentially funding a paint job on a car whose engine block has already cracked.

We’re still using death as our primary endpoint because we don’t yet have the courage—or the high-resolution data—to define a molecular baseline for "The First Departure." It’s much easier to measure a corpse than it is to measure the subtle, 1% drift in mitochondrial elasticity that happens at age 35.

We need to stop looking at when the heart stops and start looking at the Signal-to-Noise Decay in our interstitial fluids. If we can’t map the early drift—the moment the "Hepatic Sink" can no longer compensate for peripheral oxidative stress—we aren't practicing longevity science; we’re just managing a slow-motion collapse.

This requires a collaborative shift in clinical trial design. We must move away from "all-cause mortality" toward Primary Latency—measuring how long an organism can maintain a pristine molecular signature before the first pathological "noise" appears.

Are we brave enough to admit that a five-year extension of unmedicated, high-flux life is worth more to the species than a twenty-year extension of managed decline? If so, we need to stop chasing the tail of the curve and start mapping the middle. We need sensors for this, and I’m looking for collaborators who aren't afraid of "null" mortality results in exchange for high-resolution healthspan data.